Haleon plc (LON:HLN - Get Free Report)'s stock price was down 1.9% on Monday . The stock traded as low as GBX 382.60 ($4.95) and last traded at GBX 385.50 ($4.99). Approximately 14,722,720 shares traded hands during trading, a decline of 48% from the average daily volume of 28,321,533 shares. The stock had previously closed at GBX 393.15 ($5.09).
Analyst Upgrades and Downgrades
Separately, Berenberg Bank raised their price objective on Haleon from GBX 456 ($5.90) to GBX 457 ($5.92) and gave the stock a "buy" rating in a research report on Friday, February 28th.
View Our Latest Research Report on Haleon
Haleon Trading Up 0.1 %
The business's 50-day simple moving average is GBX 386.58 and its 200-day simple moving average is GBX 381.74. The company has a market cap of £34.52 billion, a PE ratio of 32.17, a P/E/G ratio of 1.49 and a beta of 0.19. The company has a current ratio of 0.84, a quick ratio of 0.93 and a debt-to-equity ratio of 53.36.
Haleon (LON:HLN - Get Free Report) last announced its quarterly earnings data on Friday, February 28th. The company reported GBX 15.80 ($0.20) earnings per share (EPS) for the quarter. Haleon had a return on equity of 6.54% and a net margin of 9.66%. As a group, analysts expect that Haleon plc will post 19.5033282 EPS for the current fiscal year.
Haleon Increases Dividend
The company also recently declared a dividend, which will be paid on Thursday, June 5th. Stockholders of record on Thursday, April 24th will be issued a dividend of GBX 4.60 ($0.06) per share. This represents a dividend yield of 1.18%. This is a positive change from Haleon's previous dividend of $2.00. The ex-dividend date is Thursday, April 24th. Haleon's payout ratio is currently 50.46%.
Haleon Company Profile
(
Get Free Report)
Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon's portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.
Featured Stories
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.